Fatty acids, free (Non-ester)-994
Test info
Nonesterified free fatty acids
Knowledge of the level of nonesterified fatty acids (NEFA) in blood plasma can be helpful in the diagnosis and management of certain diseases and disorders of metabolism and in the evaluation of prospective causes of hyperlipoproteinemia.
Specimen
Sample should be collected in the early morning after a 12-hour fast. Blood for the NEFA procedure should be collected after an overnight fast because the level of circulating nonesterified fatty acids is strongly influenced by food ingestion. If the patient has not properly fasted, the determined level of NEFA will be elevated and not directly comparable to a normal range derived from fasting normal controls.
Immediatley following collection, mix sample by gently inverting 5 times
- Allow sample to clot for a minimum of 30 minutes
- Spin within two (2) hours of sample collection
- Transfer serum to a Screw-cap polypropylene frozen transport vial/tube - 4mL (LabCorp), labelled as serum
- Freeze immediately
- Allow sample to clot
- Spin within two (2) hours of sample collection
- Transfer serum to a Screw-cap polypropylene frozen transport vial/tube - 4mL (LabCorp), labelled as serum
- Freeze immediately
Frozen (preferred) - 105 days
Freeze/thaw cycles - stable x6
Refrigerated - 1 day
Ambient - 4 hours
Performance
Spectrophotometry
Clinical and Interpretive info
|
Age |
Male (mEq/L) |
Female (mEq/L) |
|
0 – 30 days |
0.0 – 0.8 |
0.0 – 0.8 |
|
1 – 6 months |
0.0 – 0.9 |
0.0 – 1.1 |
|
7 months – 1 yr |
0.1 – 2.2 |
0.2 – 1.9 |
|
2 – 5 yrs |
0.2 – 2.3 |
0.1 – 2.8 |
|
6 – 12 yrs |
0.0 – 1.2 |
0.0 – 1.2 |
|
13 – 30 yrs |
0.0 – 0.8 |
0.0 – 1.0 |
|
31 – 70 yrs |
0.1 – 0.9 |
0.1 – 1.1 |
|
71 – 80 yrs |
0.2 – 0.7 |
0.1 – 1.1 |
|
>80 yrs |
0.1 – 0.9 |
0.1 – 0.9 |
A disorder of disease that causes excessive release of a lipoactive hormone (epinephrine, ACTH, GH, etc) can induce an elevation of blood level of fatty acids. A sustained release of fatty acids from adipose cells in excess of energy needs can contribute to the development of secondary hyperlipoproteinemia.